Correction to: Cost–Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand (Diabetes Therapy, (2023), 14, 3, (531-552), 10.1007/s13300-023-01371-y)

Deerochanawong C.Krittayaphong R.Romano J.G.U.Rhee N.A.Permsuwan U.Mahidol University2023-05-192023-05-192023-01-01Diabetes Therapy (2023)18696953https://repository.li.mahidol.ac.th/handle/20.500.14594/82530There are few errors in the original publication; the fourth author name is published as Nicolai R. Rhee, Novo Nordisk, Bangkok, Denmark. The correct name and affiliation is ‘‘Nicolai A. Rhee, Novo Nordisk, Bangkok, Thailand’’. There is an update in legend for Fig. 2. The correct legend given below.MedicineCorrection to: Cost–Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand (Diabetes Therapy, (2023), 14, 3, (531-552), 10.1007/s13300-023-01371-y)ErratumSCOPUS10.1007/s13300-023-01392-72-s2.0-8515136023118696961